Arrowhead Pharmaceuticals, Inc. (ARWR) Fundamentals — Income, Balance Sheet & Cash Flow | MarketCI

Arrowhead Pharmaceuticals, Inc. (ARWR) Fundamentals — Income, Balance Sheet & Cash Flow | MarketCI | MarketCI

ARWR

Market Closed

Arrowhead Pharmaceuticals, Inc.

NASDAQHealthcare Biotechnology

711 employees

CEO: Christopher R. Anzalone

Founded: 1993

$85.60

+$0.00(+NaN%)

Market Cap

12.06B

Beta

1.26

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Financial Statements

Comprehensive breakdown of financial statements and performance metrics

Gross Margin

100.0%

-5613.5%

CAGR: 56.5%

Profit after direct costs

Operating Margin

11.9%

-116.4%

CAGR: N/A

Core business profitability

Net Margin

-0.2%

-99.7%

CAGR: N/A

Bottom line profitability

Revenue Growth

23258.2%

YoY

CAGR: 56.5%

Top line growth rate

Revenue Flow Analysis

Visual flow showing how ARWR allocates revenue across expenses and profit

Fiscal Year 2025

Revenue Distribution

Flow of revenue through cost categories to net income

Gross Margin

100.0%

$829.45M

Operating Margin

11.9%

$98.35M

Net Margin

-0.2%

$-1.63M

Detailed Income Statement

Complete profit and loss breakdown with margin analysis and historical comparison

Item	2021	2022	2023	2024	2025	YoY Change
Total Revenue	138.29M	243.23M	240.74M	3.55M	829.45M	23258.2%
Cost of Revenue	—	(10.42M)	(12.49M)	(18.59M)	—	-100.0%
Gross Profit	138.29M	232.81M	228.24M	-15.04M	829.45M	-5613.5%
Operating Expenses
Research & Development	(198.98M)	(288.50M)	(342.31M)	(489.22M)	(607.16M)	24.1%
Selling, General & Administrative	(80.98M)	(124.43M)	(90.93M)	(96.82M)	(121.92M)	25.9%
General & Administrative	(80.98M)	(124.43M)	(90.93M)	(96.82M)	(121.92M)	25.9%
Depreciation & Amortization	(8.27M)	(10.42M)	(12.49M)	(18.59M)	(23.93M)	28.7%
Operating Income (EBIT)	-149.04M	-178.51M	-205.00M	-601.08M	98.35M	-116.4%
Non-Operating Items
Interest Income	6.12M	5.03M	15.30M	22.72M	37.29M	64.1%
Interest Expense	—	—	(18.33M)	(32.35M)	(89.36M)	176.2%
Other Income/Expenses (Net)	8.19M	5.80M	-1.49M	-11.38M	-46.81M	311.4%
Income Before Tax	-140.85M	-172.71M	-206.49M	-612.46M	51.53M	-108.4%
Income Tax Expense	(2.00K)	(3.79M)	(2.78M)	(2.77M)	(21.42M)	-874.1%
Net Income	-140.85M	-176.06M	-205.28M	-599.49M	-1.63M	-99.7%
Per Share Metrics
Earnings Per Share (Basic)	$-1	$-2	$-2	$-5	$-0	-99.8%
Weighted Avg Shares Outstanding	103.75M	105.43M	107.31M	119.78M	133.76M	11.7%
Weighted Avg Shares Outstanding (Diluted)	103.75M	105.43M	106.75M	119.78M	133.76M	11.7%
EBITDA	-132.58M	-162.29M	-175.67M	-561.51M	164.82M	-129.4%

Explore ARWR

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

ARWR in the Healthcare

Large Cap

Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →